naringenin has been researched along with Liver Steatosis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, S; Chu, L; Gao, F; Ji, B; Jia, G; Liu, J; Liu, Y; Wang, A; Wei, Y; Wu, W; Xie, L; Zhang, D; Zhou, F | 1 |
| Ku, KL; Lin, HJ; Lin, IH; Yeh, CC | 1 |
| Belwal, T; Farzaei, MH; Nabavi, SF; Nabavi, SM; Naseri, R; Parvizi, F; Sureda, A; Zobeiri, M | 1 |
| Adams, AC; Assini, JM; Burke, AC; Chhoker, SS; Drangova, M; Huff, MW; Kharitonenkov, A; Mulvihill, EE; Pin, CL; Sawyez, CG; Sutherland, BG; Telford, DE | 1 |
| Assini, JM; DiMattia, AS; Huff, MW; Khami, M; Koppes, JB; Mulvihill, EE; Sawyez, CG; Sutherland, BG; Whitman, SC | 1 |
| Assini, JM; Chhoker, S; Edwards, JY; Felder, SL; Gros, R; Huff, MW; Mulvihill, EE; Sawyez, CG; Sutherland, BG; Telford, DE | 1 |
1 review(s) available for naringenin and Liver Steatosis
| Article | Year |
|---|---|
Naringenin and its Nano-formulations for Fatty Liver: Cellular Modes of Action and Clinical Perspective.
Topics: Animals; Biological Availability; Fatty Liver; Flavanones; Humans; Nanostructures; Treatment Outcome | 2018 |
5 other study(ies) available for naringenin and Liver Steatosis
| Article | Year |
|---|---|
Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro.
Topics: Antioxidants; Cell Line; Fatty Liver; Flavonoids; Humans; In Vitro Techniques; Oleic Acid; Reactive Oxygen Species; Triglycerides | 2011 |
Naringenin attenuates hepatitis B virus X protein-induced hepatic steatosis.
Topics: Animals; Fatty Liver; Flavanones; Hep G2 Cells; Humans; Liver; Male; Mice; Mice, Transgenic; Sterol Regulatory Element Binding Protein 1; Trans-Activators; Viral Regulatory and Accessory Proteins | 2017 |
Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21.
Topics: Adipose Tissue; Animals; Fatty Liver; Fibroblast Growth Factors; Flavanones; Glucose Intolerance; Male; Mice; Mice, Knockout; Obesity | 2015 |
Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Cholesterol; Diet, Atherogenic; Dietary Fats; Disease Models, Animal; Disease Progression; Fatty Liver; Flavanones; Hyperinsulinism; Hyperlipidemias; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Receptors, LDL; Time Factors; Triglycerides | 2010 |
Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice.
Topics: Animals; Atherosclerosis; Cholesterol; Fatty Liver; Flavanones; Flavonoids; Inflammation; Insulin Resistance; Male; Mice; Mice, Knockout; Receptors, LDL | 2013 |